Mural Oncology (NASDAQ:MURA) is a clinical-stage biotechnology company focused on the development of engineered T cell receptor (TCR) therapies for the treatment of solid tumors. Utilizing a proprietary discovery engine, the company identifies and optimizes TCR candidates that recognize tumor-specific neoantigens presented by diverse human leukocyte antigen (HLA) molecules. This approach aims to address the limitations of current immunotherapies by expanding the range of targetable antigens and improving the precision of T cell–mediated tumor cell killing.
The company’s pipeline includes multiple lead candidates in early-phase clinical evaluation, each designed to target distinct oncogenic driver mutations and tumor-associated antigens. Through strategic collaborations and licensing agreements, Mural Oncology has broadened its preclinical and clinical footprint, positioning itself to initiate trials across the United States and Europe. Its discovery platform, which integrates high-throughput screening with in silico epitope prediction, supports the rapid advancement of new TCR constructs into Investigational New Drug (IND) applications.
Founded in 2019 and based in San Francisco, Mural Oncology emerged from a consortium of academic and industry scientists with deep expertise in immunology, oncology, and protein engineering. The company completed a successful Series A financing in late 2020 and a subsequent Series B round, securing capital to support both platform expansion and the progression of its most advanced programs into human studies. This funding has enabled the establishment of manufacturing partnerships and the expansion of its laboratory and translational research capabilities.
Mural Oncology is led by a management team with extensive experience in biopharmaceutical development, clinical operations, and regulatory affairs. The executive leadership comprises individuals who have held senior roles at leading biotech and pharmaceutical companies, while the scientific advisory board features prominent cancer immunologists and physician-scientists. Together, they guide the company’s mission to bring novel, precision TCR therapies to patients battling solid malignancies.
